{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:05:02Z","timestamp":1779357902884,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71241-1","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:06:19Z","timestamp":1774677979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-9268","authenticated-orcid":false,"given":"Man","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-9917","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-7026","authenticated-orcid":false,"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-1907","authenticated-orcid":false,"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1526-1043","authenticated-orcid":false,"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3282","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"71241_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage, J. O. & Longo, D. L. Mantle-Cell Lymphoma. N. Engl. J. Med. 386, 2495\u20132506 (2022).","journal-title":"N. Engl. J. Med."},{"key":"71241_CR2","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill, S. et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N. Engl. J. Med. 377, 1250\u20131260 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71241_CR3","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler, C. H. et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112, 2687\u20132693 (2008).","journal-title":"Blood"},{"key":"71241_CR4","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling, M. et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403, 2293\u20132306 (2024).","journal-title":"Lancet"},{"key":"71241_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","volume":"4","author":"RW Merryman","year":"2020","unstructured":"Merryman, R. W. et al. Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 4, 858\u2013867 (2020).","journal-title":"Blood Adv."},{"key":"71241_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"T Robak","year":"2018","unstructured":"Robak, T. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 19, 1449\u20131458 (2018).","journal-title":"Lancet Oncol."},{"key":"71241_CR7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel, M. J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381, 1203\u20131210 (2013).","journal-title":"Lancet"},{"key":"71241_CR8","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO-25-00690","volume":"43","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J. Clin. Oncol. 43, 2276\u20132284 (2025).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.23.01586","volume":"42","author":"C Sarkozy","year":"2024","unstructured":"Sarkozy, C. et al. Long-term follow-up of Rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA Trial: A LYSA Study. J. Clin. Oncol. 42, 769\u2013773 (2024).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund, C. W. et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br. J. Haematol. 175, 410\u2013418 (2016).","journal-title":"Br. J. Haematol."},{"key":"71241_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507\u2013516 (2013).","journal-title":"N. Engl. J. Med."},{"key":"71241_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang, M. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391, 659\u2013667 (2018).","journal-title":"Lancet"},{"key":"71241_CR13","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song, Y. et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139, 3148\u20133158 (2022).","journal-title":"Blood"},{"key":"71241_CR14","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang, M. L. et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J. Clin. Oncol. 41, 3988\u20133997 (2023).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR15","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","volume":"7","author":"LJ Deng","year":"2023","unstructured":"Deng, L. J. et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study. Blood Adv. 7, 4349\u20134357 (2023).","journal-title":"Blood Adv."},{"key":"71241_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1200\/JCO.21.02321","volume":"40","author":"E Gin\u00e9","year":"2022","unstructured":"Gin\u00e9, E. et al. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J. Clin. Oncol. 40, 1196\u20131205 (2022).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.21.01797","volume":"40","author":"P Jain","year":"2022","unstructured":"Jain, P. et al. Ibrutinib With Rituximab in first-line treatment of older patients with mantle cell lymphoma. J. Clin. Oncol. 40, 202\u2013212 (2022).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR18","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1182\/blood-2023-181216","volume":"142","author":"P Jain","year":"2023","unstructured":"Jain, P. et al. Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial. Blood 142, 3036\u20133036 (2023).","journal-title":"Blood"},{"key":"71241_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1182\/blood-2024-192939","volume":"144","author":"M Jerkeman","year":"2024","unstructured":"Jerkeman, M. et al. Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial. Blood 144, 747 (2024).","journal-title":"Blood"},{"key":"71241_CR20","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2023-179599","volume":"142","author":"C Qu","year":"2023","unstructured":"Qu, C. et al. Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma. Blood 142, 1658 (2023).","journal-title":"Blood"},{"key":"71241_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","volume":"23","author":"ML Wang","year":"2022","unstructured":"Wang, M. L. et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 23, 406\u2013415 (2022).","journal-title":"Lancet Oncol."},{"key":"71241_CR22","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107, 13075\u201313080 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71241_CR23","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase. J. Med. Chem. 62, 7923\u20137940 (2019).","journal-title":"J. Med. Chem."},{"key":"71241_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam, C. S. et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134, 851\u2013859 (2019).","journal-title":"Blood"},{"key":"71241_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown, J. R. et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 388, 319\u2013332 (2023).","journal-title":"N. Engl. J. Med."},{"key":"71241_CR26","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam, C. S. et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood 136, 2038\u20132050 (2020).","journal-title":"Blood"},{"key":"71241_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine, O. et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 388, 565\u2013575 (2016).","journal-title":"Lancet"},{"key":"71241_CR28","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41409-020-01198-2","volume":"56","author":"B Tessoulin","year":"2021","unstructured":"Tessoulin, B. et al. Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplant. 56, 1700\u20131709 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"71241_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73, 994\u20131007 (2008).","journal-title":"Kidney Int."},{"key":"71241_CR30","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter, D. J. Managing thrombocytopenia associated with cancer chemotherapy. Oncology 29, 282\u2013294 (2015).","journal-title":"Oncology"},{"key":"71241_CR31","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera, J. E. et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 23, 7013\u20137023 (2005).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR32","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson, B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17, 1244 (1999).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"71241_CR35","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang, M. L. et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N. Engl. J. Med. 386, 2482\u20132494 (2022).","journal-title":"N. Engl. J. Med."},{"key":"71241_CR36","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","volume":"4","author":"C Visco","year":"2017","unstructured":"Visco, C. et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 4, e15\u2013e23 (2017).","journal-title":"Lancet Haematol."},{"key":"71241_CR37","doi-asserted-by":"publisher","first-page":"e153283","DOI":"10.1172\/JCI153283","volume":"132","author":"S Yi","year":"2022","unstructured":"Yi, S. et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J. Clin. Investig. 132, e153283 (2022).","journal-title":"J. Clin. Investig."},{"key":"71241_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00927-2","volume":"13","author":"P Jain","year":"2023","unstructured":"Jain, P. et al. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 13, 156 (2023).","journal-title":"Blood Cancer J."},{"key":"71241_CR39","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinforma 30, 2114\u20132120 (2014).","journal-title":"Bioinforma"},{"key":"71241_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma 29, 15\u201321 (2013).","journal-title":"Bioinforma"},{"key":"71241_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 12, 323 (2011).","journal-title":"BMC Bioinforma."},{"key":"71241_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"71241_CR43","doi-asserted-by":"publisher","first-page":"qzaf072","DOI":"10.1093\/gpbjnl\/qzaf072","volume":"23","author":"S Zhang","year":"2025","unstructured":"Zhang, S. et al. The GSA Family in 2025: a broadened sharing platform for multi-omics and multimodal data. Genomics Proteom. Bioinforma. 23, qzaf072 (2025).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"71241_CR44","doi-asserted-by":"publisher","first-page":"D30","DOI":"10.1093\/nar\/gkae978","volume":"53","author":"CNCB-NGDC Members and Partners.","year":"2025","unstructured":"CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res. 53, D30\u2013d44 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71241-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:05:33Z","timestamp":1779354333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71241-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71241"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71241-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4535"}}